Pharmaceuticals

Multiple Sclerosis Drugs Market Outlook: Growth and Forecast Highlights 2030

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the multiple sclerosis drugs market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Multiple Sclerosis Drugs Market show for the 2026–2030 period?

The multiple sclerosis drugs market has seen substantial growth in recent years. This market is expected to expand from $33.46 billion in 2025 to $37.67 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. The historical expansion of this market can be linked to the initial limited availability of MS therapies, an increasing prevalence of multiple sclerosis, enhanced awareness among patients and physicians, the continued reliance on interferon-based therapies, and the growth of hospital and retail pharmacy networks.

The multiple sclerosis drugs market size is projected to experience swift expansion over the coming years. By 2030, this market is anticipated to reach $61.43 billion, growing at a compound annual growth rate (CAGR) of 13.0%. This anticipated growth is largely due to factors such as the creation of new monoclonal antibodies, the increase in oral disease-modifying therapies, the incorporation of personalized medicine into MS treatment, increased research and development spending on new therapies, and the wider use of digital health monitoring and telemedicine platforms. Key trends for the forecast period encompass an increase in the acceptance of disease-modifying therapies for multiple sclerosis, the advancement of personalized and targeted MS treatment methods, the broadening of distribution channels through hospitals and retail pharmacies, a greater inclination towards oral and parenteral administration methods, and the introduction of new immunomodulators, immunosuppressants, and monoclonal antibodies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp

What Drivers Are Shaping The Development Of The Multiple Sclerosis Drugs Market?

The multiple sclerosis drugs market experiences growth due to significant backing from both governmental and non-governmental entities. These organizations establish and fund numerous initiatives and programs aimed at improving the living standards of individuals impacted by multiple sclerosis (MS). As an illustration, the government of Alberta, collaborating with the Department of Economic Development, Trade, and Tourism in Canada, committed $1 million to the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This investment was intended to advance research and innovations, thereby deepening the understanding and improving the treatment of MS disease. CanProCo functions as a collaborative project, uniting the expertise of nearly 50 MS researchers from diverse fields across Canada. Further financial contributions to this initiative came from the Canada Brain Research, Biogen Canada, the MS Society of Canada, and Hoffmann-La Roche Limited (Roche Canada), collectively amassing a total of $10 million. Such consistent financial assistance from both government and non-government organizations significantly propels the expansion of the multiple sclerosis drugs market.

What Segment Types Are Examined In The Multiple Sclerosis Drugs Market?

The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

Subsegments:

1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate

2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab

3) By Interferons: Interferon Beta-1a, Interferon Beta-1b

4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies

Which Competitive Trends Are Impacting The Structure Of The Multiple Sclerosis Drugs Market?

Leading companies active in the multiple sclerosis drugs market are dedicated to developing inventive solutions aimed at enhancing treatment effectiveness, improving patient quality of life, and addressing the diverse needs of individuals living with multiple sclerosis. These innovative solutions involve new and creative approaches, products, or technologies designed to efficiently overcome specific challenges or problems. For example, in September 2024, Genentech, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo represents the first and only subcutaneous injection, administered by healthcare professionals, which is given twice a year and requires approximately 10 minutes, thus providing individuals with MS additional treatment options.

Who Are The Major Companies Operating In The Multiple Sclerosis Drugs Market?

Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Multiple Sclerosis Drugs Market?

North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Multiple Sclerosis Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2817&type=smp

Browse Through More Reports Similar to the Global Multiple Sclerosis Drugs Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Macular Degeneration Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795